Daxdilimab Cuts Disease Activity in Moderate-to-Severe Discoid Lupus
Phase 2 data show daxdilimab reduced disease activity in moderate-to-severe discoid lupus, a cutaneous lupus subtype with few targeted treatment options available.
Topic
Daxdilimab
Topic
Daxdilimab
Daxdilimab Improves Disease Activity in Refractory Discoid Lupus
A Phase 2 trial found daxdilimab improved disease activity in patients with treatment-refractory discoid lupus erythematosus, a h…